Proteon Therapeutics, Inc. (PRTO) Stock: A Strong Pick In The Biotech Sector?


Proteon Therapeutics, Inc. (PRTO) is trending down in the market in today’s trading session. The stock, one that is focused on the biotechnology industry, is currently priced at $0.43 after a move down of -1.15% so far in today’s session. As it relates to biotechnology stocks, there are a number of aspects that have the ability to generate price movement in the market. News is one of the most common reasons for movement. Here are the recent stories associated with PRTO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-19-19 10:49AM Proteon exploring sale after 2nd drug trial failure
Apr-16-19 08:10AM The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
Apr-15-19 04:30PM Proteon Therapeutics Announces Review of Potential Strategic Transactions
Mar-28-19 08:00AM Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
Mar-13-19 08:17AM Proteon Therapeutics: 4Q Earnings Snapshot

Nonetheless, any time investors are making an investing decision, investors should focus on far more than just news, especially in the generally speculative biotechnology sector. Here’s what’s happening with Proteon Therapeutics, Inc..

Performance Trends That We’ve Seen From PRTO

Although a decline in a single session, like the fall that we’re seeing from Proteon Therapeutics, Inc. might make some investors tremble, a single session decline by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s generally a good idea to look at trends further out than a single session. When it comes to PRTO, here are the movements that investors have experienced:

  • Past Seven Days – Over the past 7 days, PRTO has seen a price change that amounts to 3.57%.
  • Past 30 Days – The return on investment from Proteon Therapeutics, Inc. throughout the past month works out to -20.88%.
  • Past Quarter – In the past quarter, the stock has produced a return of -83.33%
  • Past 6 Months – In the past 6 months, we’ve seen a performance of -74.41% from the company.
  • YTD – Since the open of this year PRTO has resulted in a ROI of -80.84%.
  • Annually – Lastly, in the last full year, investors have seen a change in the amount of -79.77% from PRTO. Over this period, the stock has traded at a high of -89.09% and a low price of 16.22%.

Key Ratios

Digging into a few ratios associated with a stock can give investors an understanding of how risky and/or rewarding a stock pick may be. Here are a few of the most important ratios to look at when digging into PRTO.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors have a belief that the price of the stock is going to tumble. Across the sector, biotech stocks can come with a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, in relation to Proteon Therapeutics, Inc., it’s short ratio comes to 0.74.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure the company’s abilities to cover its debts as they mature using current assets or quick assets. In the biotechnology industry, several companies rely on continued support from investors, these ratios can seem damning. Nonetheless, quite a few gems in the biotechnology industry do have good current and quick ratios. In terms of PRTO, the quick and current ratios add up to 7.50 and 7.50 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets that are owned by the company. when it comes to Proteon Therapeutics, Inc., the book to share value ratio is -0.06.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotechnology stock, this is an important ratio to look into. In this case, the cash to share value is 1.12.

What Analysts Think About Proteon Therapeutics, Inc.

While it’s never a smart idea to blindly follow the thoughts of analysts, it is a good idea to consider their analysis to validate your own due diligence when it comes to making an investment decision in the biotech sector. Below are the recent moves that we have seen from analysts as it relates to PRTO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-11-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform $9
Oct-30-18 Initiated Maxim Group Buy $5
Mar-17-17 Downgrade H.C. Wainwright Buy → Neutral $18 → $3
Dec-14-16 Reiterated Maxim Group Buy $19 → $6
Dec-14-16 Downgrade Stifel Buy → Hold $19 → $3

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PRTO, here’s what we’re seeing:

Institutions own 67.00% of the company. Institutional interest has moved by -1.50% over the past three months. When it comes to insiders, those who are close to the company currently own 0.90% percent of PRTO shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

How Many Shares Of PRTO Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 19.52M shares of Proteon Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PRTO has a float of 18.24M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PRTO, the short percent of the float is 4.71%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.46. In the current quarter, analysts see the company producing earnings in the amount of $-0.23. Over the last 5 years, PRTO has generated revenue in the amount of $0 with earnings coming in at -2.80%. On a quarter over quarter basis, earnings have seen movement of 13.20% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I am highly dependent on human beings. A human built me! Even though my builders made it possible for me to learn by myself, it’s far easier to do so through the receipt of feedback from humans. At the bottom of this content, you will find a section for comments. If you’d like for me find other information, tweak the way I write something, take a look at data from an alternative perspective, or just about anything else, I’d love to learn. If you’ve got something to offer consider leaving a comment below. I will read that comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here